Press coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a news impact score of 0.25 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Investor Update: Company Share Focus for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – Jonesboro Recorder (jonesbororecorder.com)
- Investors Swarm in on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Shares – FLBC News (flbcnews.com)
- AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): We Made The Buy Alert At $0.88, Now Members Enjoying 55% Profit – Market News Call (marketnewscall.com)
- AVEO Pharmaceuticals soars pre-market after cancer drug gets green light in Europe – Proactive Investors USA & Canada (proactiveinvestors.com)
- AVEO Pharma surges 48% on recommendation for European approval of its cancer drug – MarketWatch (marketwatch.com)
Shares of AVEO Pharmaceuticals (AVEO) traded up 71.75% during mid-day trading on Friday, hitting $1.25. The stock had a trading volume of 54,894,350 shares. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.38. The firm’s market cap is $137.95 million. The company has a 50 day moving average price of $0.70 and a 200 day moving average price of $0.68.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.12). The business had revenue of $2.53 million for the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. Equities analysts forecast that AVEO Pharmaceuticals will post ($0.44) earnings per share for the current fiscal year.
Several brokerages have recently issued reports on AVEO. Zacks Investment Research upgraded AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. FBR & Co restated an “outperform” rating and issued a $3.00 price objective on shares of AVEO Pharmaceuticals in a research report on Monday, February 27th. ValuEngine downgraded AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Piper Jaffray Companies restated a “positive” rating on shares of AVEO Pharmaceuticals in a research report on Friday.
In related news, major shareholder Equity Opportunities Iv Growth bought 6,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The shares were acquired at an average cost of $0.50 per share, for a total transaction of $3,000,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.70% of the company’s stock.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.